Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$15.32 USD
+0.67 (4.57%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $18.90 +3.58 (23.37%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CSTL 15.32 +0.67(4.57%)
Will CSTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
New Strong Sell Stocks for August 1st
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
Other News for CSTL
Here are the major earnings after the close Monday
Closing Bell Movers: Palantir hits record highs on beat and raise
Castle Biosciences (CSTL) Pursues Growth with New Acquisition and Strategic Partnership
Castle Biosciences (CSTL) Outperforms with Strong Q2 Revenue Growth
12 Health Care Stocks Moving In Monday's After-Market Session